{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:14:21Z","timestamp":1793304861853,"version":"4.5.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Emerging treatment paradigms in classic Hodgkin lymphoma (cHL), which increasingly incorporate immunotherapy and response-adapted strategies, have increased the need for more accurate disease assessment tools. PET\/CT remains the cornerstone for staging and response evaluation, but has limited sensitivity for low-volume residual disease, interobserver variability, and a high false-positive in the setting of immunotherapy. Baseline clinical scores and erythrocyte sedimentation rate (ESR) provide baseline prognostic information but offer little insight into tumor biology or treatment response. Further, tissue-based molecular profiling is constrained by the paucity of Hodgkin Reed\u2013Sternberg (HRS) cells. We summarize emerging strategies, including total metabolic tumor volume (TMTV), serum thymus and activation-regulated chemokine (TARC), and circulating tumor DNA (ctDNA) for more accurate disease burden quantification, noninvasive genotyping, molecular subtyping, and minimal residual disease detection. Together, these tools have the potential to enable a multimodal approach to disease assessment, risk stratification, and response evaluation in cHL.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000832","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:00:35Z","timestamp":1779386435000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Present and Emerging Strategies for Disease Assessment in Hodgkin Lymphoma"],"prefix":"10.1097","volume":"32","author":[{"given":"Brian J.","family":"Sworder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5]]},"reference":[{"key":"R1-20260521","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/EDBK_200679","article-title":"New treatment algorithms in Hodgkin lymphoma: too much or too little?","volume":"38","author":"Spinner","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R2-20260521","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"key":"R3-20260521","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"R4-20260521","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"key":"R5-20260521","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"R6-20260521","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","article-title":"Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma","volume":"37","author":"Barrington","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R7-20260521","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"R8-20260521","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin\u2019s disease","volume":"357","author":"Ferme","year":"2007","journal-title":"N Engl J Med"},{"key":"R9-20260521","doi-asserted-by":"crossref","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","article-title":"Hodgkin lymphoma, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Hoppe","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"R10-20260521","doi-asserted-by":"crossref","first-page":"e0283694","DOI":"10.1371\/journal.pone.0283694","article-title":"Interobserver variability in interim PET assessment in Hodgkin lymphoma\u2014reasons and solutions","volume":"18","author":"Georgi","year":"2023","journal-title":"PLoS ONE"},{"key":"R11-20260521","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"issue":"suppl 1","key":"R12-20260521","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2025-1851","article-title":"Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: imaging sub-analysis of phase 3 S1826 study","volume":"146","author":"Bartlett","year":"2025","journal-title":"Blood"},{"key":"R13-20260521","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"key":"R14-20260521","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1182\/blood.2023020326","article-title":"The next frontier: enter PD-1 and exit PET scans?","volume":"141","author":"Mei","year":"2023","journal-title":"Blood"},{"key":"R15-20260521","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s disease. International prognostic factors project on advanced Hodgkin\u2019s disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"R16-20260521","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1200\/JCO.22.02473","article-title":"The advanced-stage Hodgkin lymphoma international prognostic index: development and validation of a clinical prediction model from the HoLISTIC consortium","volume":"41","author":"Rodday","year":"2023","journal-title":"J Clin Oncol"},{"key":"R17-20260521","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1053\/j.seminhematol.2024.05.001","article-title":"The biology of classical Hodgkin lymphoma","volume":"61","author":"Kosydar","year":"2024","journal-title":"Semin Hematol"},{"key":"R18-20260521","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0360-3016(85)90358-X","article-title":"A multivariate analysis of prognostic factors in early stage Hodgkin\u2019s disease","volume":"11","author":"Tubiana","year":"1985","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R19-20260521","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7326\/0003-4819-114-5-361","article-title":"Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group","volume":"114","author":"Henry-Amar","year":"1991","journal-title":"Ann Intern Med"},{"key":"R20-20260521","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1158\/2643-3230.BCD-22-0128","article-title":"Molecular evolution of classic Hodgkin lymphoma revealed through whole-genome sequencing of Hodgkin and Reed-Sternberg cells","volume":"4","author":"Maura","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"R21-20260521","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"key":"R22-20260521","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1182\/blood-2012-05-428896","article-title":"Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma","volume":"120","author":"Tiacci","year":"2012","journal-title":"Blood"},{"key":"R23-20260521","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.2967\/jnumed.119.227249","article-title":"Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden","volume":"60","author":"Barrington","year":"2019","journal-title":"J Nucl Med"},{"key":"R24-20260521","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1182\/bloodadvances.2021006923","article-title":"A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma","volume":"6","author":"Thieblemont","year":"2022","journal-title":"Blood Adv"},{"key":"R25-20260521","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","article-title":"Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"41","author":"Sasanelli","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R26-20260521","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"key":"R27-20260521","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","article-title":"Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"key":"R28-20260521","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.3324\/haematol.2021.280004","article-title":"High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline","volume":"107","author":"Rossi","year":"2022","journal-title":"Haematologica"},{"key":"R29-20260521","doi-asserted-by":"crossref","first-page":"23195","DOI":"10.1038\/s41598-021-02734-w","article-title":"Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin\u2019s lymphoma","volume":"11","author":"Pinochet","year":"2021","journal-title":"Sci Rep"},{"key":"R30-20260521","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.2967\/jnumed.124.267789","article-title":"International benchmark for total metabolic tumor volume measurement in baseline (18)F-FDG PET\/CT of lymphoma patients: a milestone toward clinical implementation","volume":"65","author":"Boellaard","year":"2024","journal-title":"J Nucl Med"},{"key":"R31-20260521","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3390\/hematolrep17060060","article-title":"AI improves agreement and reduces time for quantifying metabolic tumour burden in Hodgkin lymphoma","volume":"17","author":"Sadik","year":"2025","journal-title":"Hematol Rep"},{"key":"R32-20260521","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin\u2019s lymphoma","volume":"9","author":"Kuppers","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"R33-20260521","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin\u2019s lymphoma: increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J Clin Oncol"},{"key":"R34-20260521","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2141.2007.06964.x","article-title":"Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22","volume":"140","author":"Niens","year":"2008","journal-title":"Br J Haematol"},{"key":"R35-20260521","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1158\/0008-5472.CAN-05-0100","article-title":"Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin\u2019s disease: potential for a prognostic factor","volume":"65","author":"Weihrauch","year":"2005","journal-title":"Cancer Res"},{"key":"R36-20260521","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3324\/haematol.2011.053199","article-title":"Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin\u2019s lymphoma","volume":"97","author":"Plattel","year":"2012","journal-title":"Haematologica"},{"key":"R37-20260521","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajh.23361","article-title":"Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma","volume":"88","author":"Sauer","year":"2013","journal-title":"Am J Hematol"},{"key":"R38-20260521","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.leukres.2017.09.018","article-title":"Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma","volume":"62","author":"Guidetti","year":"2017","journal-title":"Leuk Res"},{"key":"R39-20260521","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjh.16514","article-title":"Interim thymus and activation regulated chemokine versus interim (18) F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation","volume":"190","author":"Plattel","year":"2020","journal-title":"Br J Haematol"},{"key":"R40-20260521","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/hon.2775","article-title":"Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy","volume":"38","author":"Viviani","year":"2020","journal-title":"Hematol Oncol"},{"key":"R41-20260521","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1182\/bloodadvances.2025015837","article-title":"Serum TARC: a biomarker for early detection or exclusion of relapse in classic Hodgkin lymphoma","volume":"9","author":"Teesink","year":"2025","journal-title":"Blood Adv"},{"key":"R42-20260521","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer Cell"},{"key":"R43-20260521","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","article-title":"Integrating genomic features for non-invasive early lung cancer detection","volume":"580","author":"Chabon","year":"2020","journal-title":"Nature"},{"key":"R44-20260521","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2017.74.5281","article-title":"Minimal residual disease assessment in lymphoma: methods and applications","volume":"35","author":"Herrera","year":"2017","journal-title":"J Clin Oncol"},{"key":"R45-20260521","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s11864-024-01201-8","article-title":"Circulating tumor DNA in diffuse large B-cell lymphoma: from bench to bedside?","volume":"25","author":"Cherng","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"R46-20260521","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrc3066","article-title":"Cell-free nucleic acids as biomarkers in cancer patients","volume":"11","author":"Schwarzenbach","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"R47-20260521","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/bloodadvances.2021006415","article-title":"Risk profiling of patients with relapsed\/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA","volume":"6","author":"Herrera","year":"2022","journal-title":"Blood Adv"},{"key":"R48-20260521","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","article-title":"Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction","volume":"178","author":"Kurtz","year":"2019","journal-title":"Cell"},{"key":"R49-20260521","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"key":"R50-20260521","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1200\/JCO-25-01534","article-title":"Remission assessment by circulating tumor DNA in large B-cell lymphoma","volume":"43","author":"Roschewski","year":"2025","journal-title":"J Clin Oncol"},{"key":"R51-20260521","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3324\/haematol.2019.237719","article-title":"Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study","volume":"106","author":"Camus","year":"2021","journal-title":"Haematologica"},{"key":"R52-20260521","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"R53-20260521","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1200\/JCO.23.01867","article-title":"Circulating tumor DNA sequencing for biologic classification and individualized risk stratification in patients with Hodgkin lymphoma","volume":"42","author":"Heger","year":"2024","journal-title":"J Clin Oncol"},{"key":"R54-20260521","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"key":"R55-20260521","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood-2025-351","article-title":"Circulating tumor DNA analyses of molecular tumor burden are superior to PET-assessed responses in patients with advanced stage classic Hodgkin lymphoma treated on SWOG S1826","volume":"146","author":"Paczkowska","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"R56-20260521","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1182\/blood-2025-5408","article-title":"Precise-HL trial: personalized reduction of chemotherapy intensity through ctDNA evaluation in advanced Hodgkin lymphoma","volume":"146","author":"Lynch","year":"2025","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000832","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:00:41Z","timestamp":1779386441000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":56,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000832","relation":{},"ISSN":["1540-336X"],"issn-type":[{"value":"1540-336X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2026-02-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}